Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Cortagen

Ala-Glu-Asp-Pro Khavinson Bioregulator

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Cortagen (AEDP) rests on animal and in-vitro work only: the primary finding is a 2000 rat sciatic-nerve study reporting 27 to 40 percent gains in fiber growth and conduction velocity (Turchaninova/Kolosova, Bull Exp Biol Med), supported by microarray and chromatin-decondensation experiments (Anisimov 2004; Khavinson and Lezhava 2014). No published human trials, no pharmacokinetic data, and no Western replication exist, so the honest grade is 1, not 2.

FDA
Not approved (USA); sold as research chemical, not for human consumption
WADA
Not listed on the WADA Prohibited List

Reference only. Not medical advice.

What can go wrong

Animal-only evidence, no human trials, unapproved research chemical of uncertain purity and long-term safety.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Cortagen. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A Khavinson neuropeptide bioregulator targeting nervous-system tissue and peripheral nerve regeneration. Russian clinical data only.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Peripheral nerve regeneration (Russian data)
  • Neuroprotection

How it is supposed to work

Cortagen is a synthetic peptide (alanine, glutamic acid, aspartic acid, proline) directed at the cerebral cortex, promoted for neural recovery and cognitive support in the bioregulator framework. Its tissue-specific mechanism is unproven in controlled human studies.

Cortagen is a synthetic short peptide, a defined-sequence second-generation bioregulator aimed at cortical tissue, closely related in purpose to Pinealon and to the older cortex extract drug Cortexin.

Type
Synthetic short peptide
Target
Cerebral cortex
Generation
Second (defined)
Use
Pulsed courses
Evidence
Preclinical and Russian
Western RCT
None

A Cortex Bioregulator, Twin To Pinealon In Evidence

Cortagen is essentially the cortex-focused twin of Pinealon, and it carries the identical evidentiary situation. The mechanism is the family’s contested signature, direct peptide-driven gene regulation in the target tissue, here the cortex, and it is not established outside the originating group. The cognitive and neuroprotective claims are preclinical and Russian, without independent human trials. Its frequent pairing with Pinealon as a cognitive stack is a marketing and protocol convention from within the same ecosystem rather than something validated by outside evidence. Cortagen is best read not as a distinct discovery but as another tissue-labeled member of a system whose whole evidence base comes from one place.

Safety in detail

No published human safety or pharmacokinetic data exist for Cortagen. Vendor-supplied material is labeled for research use only, and any Russian clinical familiarity is associated with the separate Cortexin extract, not this synthetic tetrapeptide.

  • Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
  • Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
  • Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
  • Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.

Children and teenagers

Cortagen has no validated pediatric use and is an unapproved injected peptide. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Cortagen reaches users only through the bioregulator gray market and longevity vendors. There is no approved product, and it is often sold as part of a cortex-and-pineal cognitive bundle.

How we got here

Cortagen was created by Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology through directed synthesis, after amino-acid analysis of Cortexin, a bovine cerebral-cortex peptide hydrolysate long used in Russian neurology, pointed to Ala-Glu-Asp-Pro as an active fragment. It sits within the same Khavinson bioregulator lineage as epithalon, vilon, and pinealon, all ultrashort peptides claimed to act on tissue-specific gene expression. It should not be conflated with Cortexin, the parent extract drug, whose Russian clinical record is separate and larger. Today Cortagen circulates mainly as a research-chemical peptide rather than an approved medicine, and in this library it is stored under the mismatched legacy id `pinealon2`.

Cortagen was developed as a defined-sequence cortex bioregulator at the St. Petersburg institute, the modern peptide refinement of the brain-extract tradition represented by Cortexin.

The numbers behind the grade

Type
Peptide (Ala-Glu-Asp-Pro)
Target
Brain / cortex
Russia
Bioregulator line
FDA
Not approved
Evidence
Single-tradition
Western RCTs
None

The people taking it

A cortex-directed cognitive bioregulator, a synthetic counterpart to the extract Cortexin.

Cortagen’s users are cognitive-longevity enthusiasts and the bioregulator-protocol community, frequently using it alongside Pinealon.

Used as a cognitive and neural-recovery bioregulator within Russian-tradition protocols; not independently confirmed.

Set against the alternatives

Cortagen is the cortex counterpart to Pinealon’s broader brain focus, the defined-peptide modern relative of the Cortexin brain extract, and a member of the same system as Epithalon. Against a Russian synthetic neuropeptide like Semax, which has more human data, Cortagen’s evidence is thinner. Its identity is largely defined by its place in the family rather than a distinct independent profile.

What we do not know

  • Whether independent, Western randomized trials confirm any of the claimed clinical effects.
  • Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
  • Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
  • Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.

Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Cortagen.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • Khavinson group studies2000s

    Reported cortical and neural-recovery effects within the bioregulator literature.

  • Independent replicationnone notable

    No independent Western trials of Cortagen exist.